Here's Why Shares in This Hot Healthcare Stock Surged This Week
The bioprocessing market is about to recover. That's the conclusion from Repligen's (NASDAQ: RGEN) second-quarter earnings report released earlier in the week and the reason for the stock's 17.7% ascendancy in the week to Friday morning.
A positive view of Repligen's recovery is supported when examining 's recent results, released a week earlier. Danaher is a much larger company selling life sciences and diagnostics platforms and consumables; however, its bioprocessing business attracted the most attention on the earnings call.
Danaher's bioprocessing revenue declined by high single digits in the quarter, and management still expects a low-single-digit decline for the full year. Still, management also said its bioprocessing core revenue would exit the year with a high-single-digit growth rate.
Source Fool.com
Danaher Corp. Stock
With 28 Buy predictions and not a single Sell prediction Danaher Corp. is an absolute favorite of our community.
With a target price of 251 € there is a slightly positive potential of 2.01% for Danaher Corp. compared to the current price of 246.05 €.
